Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovarian Syndrome
Conditions
Polycystic Ovarian Syndrome
Trial Timeline
Nov 1, 2008 → Feb 1, 2012
NCT ID
NCT01185704About Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH) is a phase 3 stage product being developed by Merck for Polycystic Ovarian Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01185704. Target conditions include Polycystic Ovarian Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01185704 | Phase 3 | Completed |
Competing Products
20 competing products in Polycystic Ovarian Syndrome